Short Interest in Aethlon Medical, Inc. (NASDAQ:AEMD) Decreases By 60.4%

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 56,100 shares, a drop of 60.4% from the March 31st total of 141,600 shares. Based on an average daily volume of 327,200 shares, the short-interest ratio is currently 0.2 days. Currently, 0.4% of the company’s shares are sold short.

Aethlon Medical Stock Up 4.8 %

Shares of NASDAQ AEMD opened at $0.42 on Wednesday. The business has a 50-day simple moving average of $0.41 and a two-hundred day simple moving average of $0.49. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $1.79. The company has a market cap of $6.68 million, a P/E ratio of -0.26 and a beta of 1.71.

Aethlon Medical (NASDAQ:AEMD) last released its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. Equities research analysts anticipate that Aethlon Medical will post -0.73 EPS for the current year.

Institutional Trading of Aethlon Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC purchased a new stake in Aethlon Medical in the fourth quarter worth approximately $25,000. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Aethlon Medical in the 4th quarter worth approximately $26,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical during the 4th quarter worth approximately $31,000. Virtu Financial LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $81,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Aethlon Medical during the fourth quarter valued at approximately $186,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AEMD. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research report on Monday, March 10th. StockNews.com began coverage on shares of Aethlon Medical in a research report on Tuesday. They issued a “sell” rating on the stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.